ABSTRACTPseudomonas sp. strain LLC-1 (NBRC 111237), isolated from soil, metabolizes lignin-derived low-molecular-weight compounds and utilizes vanillin and vanillic acid as its sole sources of carbon. Here, we report the draft genome sequence of Pseudomonas sp. strain LLC-1.

01 Jan 2015·The Journal of Poultry Science

Effects of Probiotics on the Expression and Localization of Avian β-defensins in the Proventriculus of Broiler Chicks

Author: Yoshimura, Yukinori ; Igarashi, Yasumi ; Isobe, Naoki ; Mohammed, Elsayed S. I.

The aim of this study was to determine the effects of probiotics-feeding on the gene expression and protein localization of avian β-defensins (AvBDs) in the proventriculus of broiler chicks.Male broiler chicks were arranged in 3 groups: control group, probiotics group I and probiotics group II, which were fed with starter rations containing 0%, 0.2% or 0.4% probiotics, resp., from day 0 (D0; at one day old) to D14.Proventriculi in all groups were collected at D0, D7 and D14 for anal. of AvBDs expression and AvBD12 protein localization.The expression of AvBDs genes was examined by reverse transcription-PCR and changes in the expression upon probiotics-feeding were examined by real-time PCR.The AvBD12 localization was examined by immunohistochem., and d. of immunoreaction products was examined by image anal. under a microscope.Out of 14 AvBDs genes, seven AvBDs were detected in the proventriculus of chicks, namely, AvBD1, 2, 4, 6, 7, 10 and 12.The expression of the 7 detected genes did not show any significant differences between control and probiotics groups at D7 and D14.The immunoreactive (ir) -AvBD12 was localized in surface epithelium and cells in the connective tissues of proventricular glands.The ir-AvBD12 d. in surface epithelium was significantly higher at D7 than at D0 or D14 in control group.At D7 and D14, the ir-AvBD12 d. was significantly lower in probiotics groups than in control group.The ir-AvBD12 cells in proventricular gland increased in number with age; however, there were no significant differences between control and probiotics groups at D7 and D14.These results suggest that, although probiotics-feeding does not affect the gene expression of AvBDs, it may induce AvBD12 secretion from the surface epithelium of the proventriculus in broiler chicks.

01 Jan 2014·Biological and Pharmaceutical BulletinQ4 · MEDICINE

Development of Strain-Specific PCR Primers for Quantitative Detection of <i>Bacillus mesentericus</i> Strain TO-A in Human Feces

Q4 · MEDICINE

Article

Author: Seo, Genichiro ; Benno, Yoshimi ; Sato, Naoki

Strain-specific polymerase chain reaction (PCR) primers for detection of Bacillus mesentericus strain TO-A (BM TO-A) were developed. The randomly amplified polymorphic DNA (RAPD) technique was used to produce potential strain-specific markers. A 991-bp RAPD marker found to be strain-specific was sequenced, and two primer pairs specific to BM TO-A were constructed based on this sequence. In addition, we explored a more specific DNA region using inverse PCR, and designed a strain-specific primer set for use in real-time quantitative PCR (qPCR). These primer pairs were tested against 25 Bacillus subtilis strains and were found to be strain-specific. After examination of the detection limit and linearity of detection of BM TO-A in feces, the qPCR method and strain-specific primers were used to quantify BM TO-A in the feces of healthy volunteers who had ingested 3×10(8) colony forming unit (CFU) of BM TO-A per day in tablets. During the administration period, BM TO-A was detected in the feces of all 24 subjects, and the average number of BM TO-A detected using the culture method and qPCR was about 10(4.8) and 10(5.8) cells per gram of feces, respectively. Using the qPCR method, BM TO-A was detected in the feces of half of the subjects 3 d after withdrawal, and was detected in the feces of only one subject 1 week after withdrawal. These results suggest that the qPCR method using BM TO-A strain-specific primers is useful for the quantitative detection of this strain in feces.

News (Medical) associated with TOA Pharmaceuticals Co., Ltd.

16 Aug 2022

·www.prnewswire.com

The Worldwide OTC Artificial Tears Industry is Expected to Reach $6.15 Billion by 2027

DUBLIN, Aug. 16, 2022 /PRNewswire/ -- The "Global OTC Artificial Tears Market (2022-2027) by Product, Container Type, Formulation, Application, Distribution Channel, , Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global OTC Artificial Tears Market is estimated to be USD 4.85 Bn in 2022 and is expected to reach USD 6.15 Bn by 2027, growing at a CAGR of 4.85%. Market Dynamics Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks. Company Profiles The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are AbbVie Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Johnson & Johnson, Nicox S.A., OASIS Medical, OCuSOFT Inc., Santen Pharmaceutical Co. Ltd., etc. Countries Studied America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas) Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe) Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA) Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific) Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global OTC Artificial Tears Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global OTC Artificial Tears Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Why buy this report? The report offers a comprehensive evaluation of the Global OTC Artificial Tears Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies. The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry. The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report. The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies. The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool. Key Topics Covered: 1 Report Description 2 Research Methodology 3 Executive Summary 4 Market Dynamics 4.1 Drivers 4.1.1 Rising Geriatric Population and Diabetes and Nutritional Deficiencies 4.1.2 Increasing Prevalence of Dry Eye Syndrome (DES) 4.1.3 Increasing Utilization of Electronics 4.2 Restraints 4.2.1 Rising Concerns Associated with Eye Drops 4.3 Opportunities 4.3.1 Development of Novel Approach 5 Market Analysis 5.1 Regulatory Scenario 5.2 Porter's Five Forces Analysis 5.3 Impact of COVID-19 5.4 Ansoff Matrix Analysis 6 Global OTC Artificial Tears Market, By Product 6.1 Introduction 6.2 Solution 6.3 Ointment 6.4 Emulsion 6.5 Gel 6.6 Spray Solution 6.7 Suspensions 7 Global OTC Artificial Tears Market, By Container Type 7.1 Introduction 7.2 Plastic Single Dose Container 7.3 Plastic Multi-Dose Containers 7.3.1 Preservative-Free System 7.3.2 Preserved System 7.4 Spray 7.4.1 Preservative-Free System 7.4.2 Preserved System 8 Global OTC Artificial Tears Market, By Formulation 8.1 Introduction 8.2 Preservative Based 8.3 Non-Preservative Based 9 Global OTC Artificial Tears Market, By Application 9.1 Introduction 9.2 Dry Eye Syndrome 9.3 Allergies 9.4 Infections 9.5 UV & Blue Light Protection 9.6 Contact Lens Moisture Retention 9.7 Others 10 Global OTC Artificial Tears Market, By Distribution Channel 10.1 Introduction 10.2 Hospital Pharmacies 10.3 Drug Store & Retail Pharmacies 10.4 Online Pharmacies 11 Americas' OTC Artificial Tears Market 11.1 Introduction 11.2 Argentina 11.3 Brazil 11.4 Canada 11.5 Chile 11.6 Colombia 11.7 Mexico 11.8 Peru 11.9 United States 11.10 Rest of Americas 12 Europe's OTC Artificial Tears Market 12.1 Introduction 12.2 Austria 12.3 Belgium 12.4 Denmark 12.5 Finland 12.6 France 12.7 Germany 12.8 Italy 12.9 Netherlands 12.10 Norway 12.11 Poland 12.12 Russia 12.13 Spain 12.14 Sweden 12.15 Switzerland 12.16 United Kingdom 12.17 Rest of Europe 13 Middle East and Africa's OTC Artificial Tears Market 13.1 Introduction 13.2 Egypt 13.3 Israel 13.4 Qatar 13.5 Saudi Arabia 13.6 South Africa 13.7 United Arab Emirates 13.8 Rest of MEA 14 APAC's OTC Artificial Tears Market 14.1 Introduction 14.2 Australia 14.3 Bangladesh 14.4 China 14.5 India 14.6 Indonesia 14.7 Japan 14.8 Malaysia 14.9 Philippines 14.10 Singapore 14.11 South Korea 14.12 Sri Lanka 14.13 Thailand 14.14 Taiwan 14.15 Rest of Asia-Pacific 15 Competitive Landscape 15.1 Competitive Quadrant 15.2 Market Share Analysis 15.3 Strategic Initiatives 15.3.1 M&A and Investments 15.3.2 Partnerships and Collaborations 15.3.3 Product Developments and Improvements 16 Company Profiles 16.1 AbbVie Inc 16.2 Akorn Inc 16.3 Alcon 16.4 Bausch Health Companies Inc 16.5 Johnson & Johnson 16.6 Nicox S.A. 16.7 OASIS Medical 16.8 OCuSOFT Inc 16.9 Santen Pharmaceutical Co. Ltd 16.10 Similasan Corp 16.11 Sun Pharmaceutical Industries Ltd 16.12 URSAPHARM Arzneimittel GmbH. 17 Appendix For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Collaborate

16 Jun 2022

·www.prnewswire.com

Ophthalmic Drugs Market Attract Notable Growth Prospects with Rising Awareness on Available Diagnosis and Treatment Solutions, Says TMR Study

Increase in global older population is creating high demand for different ophthalmic drugs Players in the ophthalmic drugs market are focusing on product approvals and R&Ds in order to develop technologically advanced treatment solutions ALBANY, N.Y., June 16, 2022 /PRNewswire/ -- The global ophthalmic drugs market is projected to register growth at a CAGR of 4.1% during the forecast period of 2019 to 2027, as per analysts of a Transparency Market Research (TMR) study. The global healthcare industry is experiencing rising need for the advanced solutions for the treatment of wide range of eye disorders such as optic nerve, recurrent or chronic uveitis, retinoblastoma, and neurodegeneration retinitis pigmentosa. Moreover, FDAs of many nations are providing approvals for innovative and effectual retinal treatment solutions in order to cater to unmet requirements in eye disorders. These factors are expected to create lucrative prospects in the ophthalmic drugs market during the forecast period. Manufacturers are increasing researches in order to address common side-effects occurring due to ophthalmic drugs including blurred vision, abnormal vision, dry/irritated eyes, poor focusing ability, compromised pupil size, and color perception changes. The global ophthalmic drugs market is likely to observe sluggish growth due to these disadvantages of the drugs. The ophthalmic drugs market in North America is expected to gain sizable business prospects in the upcoming years owing to many factors such as technological advancements in the ocular therapies. Moreover, the North America ophthalmic drugs market is prognosticated to gain noteworthy expansion opportunities owing to rising efforts of regional market players to develop innovative drug delivery systems, note analysts of a research report by TMR. Request Brochure of Ophthalmic Drugs Market Research Report – Ophthalmic Drugs Market: Key Findings Government as well as private organizations of several nations globally are taking initiatives to spread awareness among people on different types of eye disorders such as glaucoma, dry eye, infection, retinal disorders, and inflammation. Moreover, they are also focusing on development of different campaigns that are focused on growing understanding about different types of advanced eye treatment solutions available in the healthcare industry. These efforts are leading to surge in the sales growth in the global ophthalmic drugs market. Healthcare professionals across the globe are increasing the adoption of varied advanced therapeutics in the treatment of eye disorders in order to offer high level of healthcare to patients. Similarly, the patient population across the globe is inclining toward opting advanced treatment solutions due to their improved spending power. These factors, in turn, are generating sizable demand prospects in the global ophthalmic drugs market, notes TMR study. Request for Analysis of COVID-19 Impact on Ophthalmic Drugs Market – Ophthalmic Drugs Market: Growth Boosters Rise in the prevalence of varied eye-related disorders across the globe is propelling the global ophthalmic drugs market Increase in the global older population is leading to increased cases of eye diseases, which in turn, is boosting the demand for ophthalmic drugs globally Get Exclusive PDF Sample Copy of Ophthalmic Drugs Market Report – Ophthalmic Drugs Market: Competition Landscape Major companies operating in the global ophthalmic drugs market are using strategies such as mergers, collaborations, joint ventures, and partnerships in order to stay competitive Several enterprises in the market for ophthalmic drugs are focusing on the development of technologically advanced products, regulatory approvals, and new product launches In order to sustain in the high level of competitions, many new players in the ophthalmic drugs market are focusing on offering specialized treatment options for specific eye diseases Make an Enquiry Before Buying – Ophthalmic Drugs Market: Key Players Some of the key players profiled in the report are: ALLERGAN Aerie Pharmaceuticals, Inc. Bayer AG Valeant Pharmaceuticals International, Inc. Novartis AG Genentech, Inc. (F. Hoffmann-La Roche Ltd.) Regeneron Pharmaceuticals, Inc. Pfizer Inc. Santen Pharmaceutical Co., Ltd. Ophthalmic Drugs Market Segmentation Product Type Prescription Drugs OTC Drugs Therapeutic Class Anti-inflammatory Drugs NSAIDs Steroids Anti-infective Drugs Anti-fungal Drugs Anti-bacterial Drugs Others Anti-glaucoma Drugs Alpha Agonist Beta Blockers Prostaglandin Analogs Combined Medication Others Anti-allergy Drugs Anti-VEGF Agents Others Disease Indication Dry Eye Glaucoma Infection/ Inflammation Retinal Disorders Wet AMD Dry AMD Diabetic Retinopathy Others Allergy Uveitis Others Distribution Channels Hospital Pharmacies Online Pharmacies Independent Pharmacies & Drug Stores Region North America Europe Asia Pacific Latin America Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Research Reports by Transparency Market Research: Glaucoma Therapeutics Market: Increase in prevalence and incidence of diabetic disorders, rise in geriatric population, improved health care as well as health care infrastructure, introduction of combination therapies, and surge in the number of awareness programs are likely to drive the global glaucoma therapeutics market during the forecast period. Dry Eye Disease Treatment Market: Rise in reported cases of dry eye disease, increase in the number of surgical procedures such as LASIK surgery, adverse effects of rising pollution levels, advances in treatment of dry eye, and introduction of new therapies are projected to drive the global dry eye disease treatment market. Dry Eye Disease Diagnostics & Treatment Market: Rise in prevalence and incidence rate of dry eye disease and increase in geriatric population are the major factors boosting the growth of the global dry eye disease diagnostics & treatment market. Dry Eye Disease Diagnostic Devices Market: Rise in prevalence and incidence rates of dry eye disease in the U.S., technical advancements in dry eye disease diagnostic devices, adverse effects of rising pollution levels, and increase in use of electronics are anticipated to propel the market during the forecast period. Retinal Disorders Treatment Market: Increase in R&D activities, rise in number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are likely to boost advancements in therapies in the retinal disorders treatment market during the forecast period. Allergy relieving Eye Drops Market: Increase in prevalence and incidence rates of eye-related disorders, high unmet needs in patients with ocular allergy, increased geriatric population, raised awareness about eye diseases in developing countries are expected to boost the allergy-relieving eye drops market during the forecast period. Macular Degeneration Treatment Market: Increase in prevalence and incidence of retinal disorders, rise in the geriatric population, high annual cost of therapy (ACOT) for pipeline drugs, improved health care as well as health care infrastructure, introduction of novel therapies, and surge in the number of awareness programs are likely to drive the global macular degeneration treatment market during the forecast period. Tablet Coatings Market: Increase in outsourcing of operations and rise in R&D activities in pharmaceuticals in developed countries are creating lucrative opportunities for players in the tablet coatings market. The global tablet coatings market is anticipated to reach more than US$ 1,543 Mn by 2031 About Us Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

Innovative DrugAcquisitionCollaborate

02 Sep 2021

·www.biospace.com

Ocuphire Pharma Presenting at Four Conferences in September 2021

Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021 Cantor Virtual Global Healthcare Conference on September 27-30, 2021 FARMINGTON HILLS, Mich., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, President and Chief Executive Officer will be presenting corporate overviews at the Euro Forums 2021 Virtual Retina Forum on Wednesday, September 8 as well as participating in 1X1 investor meetings at the HC Wainwright Virtual 23rd Annual Global Investment Conference on Monday, September 13 at 7:00am EDT, the Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21 at 11:35am EDT, and the Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 10:00am EDT. Euro Forums 2021 Virtual Retina Forum on September 8, 2021 Title: Ocuphire Pharma (OCUP) Date: Wednesday, September 8, 2021 Presenter: Mina Sooch, CEO Conference Link: HC Wainwright Virtual 23rd Annual Global Investment Conference – September 13-15, 2021 Title: Ocuphire Pharma (OCUP) Company Presentation Date: Monday, September 13, 2021 Time: Available after 7:00 AM EDT and 1X1 Meetings Presenter: Mina Sooch, CEO Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit – September 20-23, 2021 Title: Ocuphire Pharma (OCUP) Company Presentation Date: Tuesday, September 21, 2021 Time: 11:35 AM EDT and 1X1 Meetings Presenter: Mina Sooch, CEO Webcast Link: Cantor Virtual Global Healthcare Conference – September 27-30, 2021 Title: Ocuphire Pharma (OCUP) Date: Tuesday, September 28, 2021 Time: 10:00 AM EDT and 1X1 Meetings Presenter: Mina Sooch, CEO If you are interested in arranging a 1X1 meeting request or listening live or to a replay of the company fireside chats with the biotech research analyst, please contact your bank conference representative or ir@ocuphire.com. For more details, please see the Investors and Events section of Ocuphire’s corporate website. About Ocuphire Pharma Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including reversal of pharmacologically-induced mydriasis (RM), presbyopia, and dim light or night vision disturbances (NVD), and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit to learn more about Ocuphire’s completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit . Ocuphire Contacts Mina Sooch, President & CEO Ocuphire Pharma, Inc. ir@ocuphire.com Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com

100 Deals associated with TOA Pharmaceuticals Co., Ltd.

100 Translational Medicine associated with TOA Pharmaceuticals Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lactobacillin/clostridium butyricum/bacillus mesentericus(Toa Pharmaceuticals)	Constipation More	Approved
Tosufloxacin Tosilate Hydrate ( Bacterial DNA gyrase x Topoisomerase IV )	Dacryocystitis More	Approved
Magnesium Sulfate Hydrate/Glucose	Eclampsia More	Approved
Tobramycin ( 30S subunit )	Keratitis More	Approved
Acyclovir ( DNA-directed DNA polymerase )	Keratitis, Herpetic More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis